Intravenous injection of siRNAs against ARHGEF4, CCDC88A, LAMTOR2, mTOR, NUP85, and WASF2, which were modified with FA to allow binding to the FA receptor and PEG-COL nanoparticles, enabled target siRNA-FA-PEG-COL nanoparticle-mediated passive delivery to human PDAC tumor cells and promoted efficient siRNA endocytosis of these siRNA particles via the FA receptor on PDAC cells. The gene discussed is LAMTOR2; the disease is neoplasm.